Clinical and metabolic effects of medroxyprogesterone acetate and ethinyl estradiol plus drospirenone in women with polycystic ovary syndrome

Basit Öğe Kaydı
dc.contributor.authorOzdemir, Suna
dc.contributor.authorGorkemli, Huseyin
dc.contributor.authorGezginc, Kazim
dc.contributor.authorOzdemir, Mustafa
dc.contributor.authorKiyici, Aysel
dc.date.accessioned2020-03-26T17:26:30Z
dc.date.available2020-03-26T17:26:30Z
dc.date.issued2008
dc.departmentSelçuk Üniversitesien_US
dc.description.abstractObjectives: To investigate the effects of treatment with medroxyprogesterone acetate (MPA), 10 days per month for 6 months, on lipid and carbohydrate metabolism in women with polycystic ovary syndrome (PCOS). Methods: Sixty-three women with PCOS were randomized to receive MPA or ethinyl estradiol plus drospirenone. Results: There were no changes in lipid or carbohydrate metabolism in the MPA group, but serum levels of luteinizing hormone (P < 0.001) and total testosterone (P < 0.003) significantly decreased, as did the free androgen index (P < 0.02) and acne (P < 0.03) and seborrhea (P < 0.04) scores. In the ethinyl estradiol plus drospirenone group lipid and hormone values significantly increased whereas acne, seborrhea, hair Loss, and Ferriman-Gallwey scores decreased. There was no statistically significant change in the total cholesterol to high-density cholesterol ratio in either group. Conclusion: Treatment of PCOS patients with MPA provided good menstrual cycle control, beneficial changes in hormonal values associated with hyperandrogenism, and no significant changes in lipid or carbohydrate metabolism. (c) 2008 International Federation of Gynecology and Obstetrics. Published by Elsevier Ireland Ltd. All, rights reserved.en_US
dc.identifier.doi10.1016/j.ijgo.2008.05.017en_US
dc.identifier.endpage49en_US
dc.identifier.issn0020-7292en_US
dc.identifier.issn1879-3479en_US
dc.identifier.issue1en_US
dc.identifier.pmid18635183en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.startpage44en_US
dc.identifier.urihttps://dx.doi.org/10.1016/j.ijgo.2008.05.017
dc.identifier.urihttps://hdl.handle.net/20.500.12395/22254
dc.identifier.volume103en_US
dc.identifier.wosWOS:000260275300011en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherWILEYen_US
dc.relation.ispartofINTERNATIONAL JOURNAL OF GYNECOLOGY & OBSTETRICSen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.selcuk20240510_oaigen_US
dc.subjectCarbohydrate metabolismen_US
dc.subjectDrospirenoneen_US
dc.subjectLipid metabolismen_US
dc.subjectMedroxyprogesterone acetateen_US
dc.subjectPolycystic ovary syndromeen_US
dc.titleClinical and metabolic effects of medroxyprogesterone acetate and ethinyl estradiol plus drospirenone in women with polycystic ovary syndromeen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu